

#### October 28, 2024

BSE Limited	National Stock Exchange of India Ltd.			
Corporate Relationship Department	Exchange Plaza,			
P.J. Towers,	Bandra-Kurla Complex,			
Dalal Street, Fort,	Bandra (East)			
Mumbai - 400 001	Mumbai - 400 051			
Scrip Code : 506109	Symbol : GENESYS			

Dear Sirs,

Subject: Statement of Deviation or Variation or Utilization of funds raised under Preferential Issue - Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended September 30, 2024

In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter ended September 30, 2024 as reviewed by the Audit Committee.

You are requested to take the above on your records.


Thanking You,

Yours Faithfully, for **Genesys International Corporation Limited** 

Vineet Chopra Vice President - Legal & Company Secretary

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603

Website: www.igenesys.com; E-mail:investors@igenesys.com





	ligations & Disclosure Requirements) Regulations, D/CMD/162/2019 dated December 24, 2019				
Name of the Listed Entity	Genesys International Corporation Limited  Public Issues / Rights Issues / Preferential Issues/ QIP / Others				
Mode of Fund Raising					
Date of Raising Funds	January 12, 2024				
Amount Raised	Rs. 56,24,97,637.50				
Report filed for Quarter ended	September 30, 2024				
Monitoring Agency, if applicable	Not Applicable				
Is there a Deviation / Variation in use of funds raised	No				
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable				
Explanation for the Deviation / Variation	Not Applicable				
Comments of the Audit Committee after review	None				
Comments of the auditors, if any	Not applicable				

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603

Website: www.igenesys.com; E-mail:investors@igenesys.com





Sr. no.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/ Variation for the quarter according to applicable object	Remarks if any
a)	Combination of part funding of the capital expenditure, support growth plans of the Company, working capital requirements, repayment of loans, investments and general corporate purposes or any combination thereof to pursue the business objects of the Company	Not Applicable	Rs. 56,24,97,6 37.50	Nil	Rs. 56,24,97, 637.50	Nil	Kindly refer Note

Note: 1. The members of the Company on July 09, 2022 had approved issue of 13,04,345 Warrant convertible into equity shares at price of Rs.460/- to Malabar India Fund Limited.

The Company received Rs.44,99,99,025 i.e balance 75% of the issue price on January 12, 2024 for allotment of equity shares pursuant to exercising of warrants into equity shares. The Company on 12th January, 2024 allotted 13,04,345 equity shares to Malabar India Fund Limited.

2. The members of the Company on 9th July, 2022 had approved issue of 3,19,145 Warrant convertible into equity shares at price of Rs.470/- to Sundar Iyer.

The Company received Rs.11,24,98,612.50 i.e balance 75% of the issue price on 11th January, 2024 for allotment of equity shares pursuant to exercising of warrants into equity shares. The Company on 12th January, 2024 allotted 3,19,145 equity shares to Sundar Iyer.

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603

Website: www.igenesys.com; E-mail:investors@igenesys.com





3. All the fund raised on 12th January 2024 on the conversion of warrants into equity shares have been fully utilized and there was no deviation, therefore the requirements for reporting of Statement of Deviation for the said fund raised through the preferential issue will not be required for the next quarter.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the fund have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

For Genesys International Corporation Limited

Vineet Chopra Vice President - Legal & Company Secretary

Date: 28.10.2024 Place: Mumbai

Regd. Office: 73-A, SDF-III, SEEPZ, Andheri (E), Mumbai-400 096, India Tel.: +91-22-2829 0303; +91-22-4488 4488; Fax: +91-22-2829 0603

Website: www.igenesys.com; E-mail:investors@igenesys.com

